ISTH 2023 | HAVEN-6 trial updates: emicizumab in non-severe hemophilia A
In this video, Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, discusses updated results from the Phase III HAVEN-6 trial (NCT04158648), which is evaluating the safety and efficacy of emicizumab in patients with moderate or mild hemophilia A (HA). Prof. Oldenburg summarizes the promising results obtained in this study, and further discusses the value of emicizumab in the treatment of patients with HA. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
JO: reimbursed for attending symposia/congresses and/or received honoraria and/or funds for research from Bayer, Biogen Idec, Biomarin, Biotest, Chugai, CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum and Takeda.
